Epigral net profit falls 38% YoY as input costs rise
NiveshIQ
NSE: EPIGRAL
Epigral Ltd.
₹1,105.30▼ ₹22.00 (-1.95%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on EPIGRAL. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Epigral Ltd.
Epigral Limited is a leading Basic Materials company in India, primarily engaged in the manufacturing and sale of chlor-alkali and derivative products. The company's key revenue drivers include chlorinated polyvinyl chloride (CPVC) resin, epichlorohydrin, and hydrogen peroxide. Despite recent challenges, with net profit falling 38% YoY due to rising input costs, Epigral has announced plans to invest ₹600 crore on new plants in Gujarat, which is expected to drive growth. The company has also planned a ₹600 crore expansion into epoxy resins and methyl phenyl polycarbonate (MPP). Epigral's products have a wide range of applications across various industries, including construction, electronics, and pharmaceuticals. With a strong presence in the Indian market, Epigral is well-positioned to ben
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹1,930 Cr -11.80% | ₹2,550 Cr +32.10% | ₹2,527 Cr -0.90% |
| EBITDA Margin | 24.92% | 27.84% | 22.40% |
| Net Profit | ₹196.00 Cr -44.50% | ₹358.00 Cr +82.70% | ₹331.95 Cr -7.30% |
| EPS | ₹47.13 | ₹84.40 | ₹76.95 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Epigral Q1 profit down 38% to ₹100 crore; to invest ₹600 crore on new plants in Gujarat
Epigral Q1 profit down 38% to ₹100 crore; to invest ₹600 crore on new plants in Gujarat
🔒
+ 3 more stories about Epigral Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹705 Cr, PAT ₹100 Cr, EPS ₹23.12, EBITDA margin 26.0%. Growth context: revenue QoQ -4.2%, PAT QoQ +23.2%.
Management commentary highlights new capacity additions and capex deployment as key near-term growth drivers, with succe...
FY26 (last completed FY): revenue ₹2, 527 Cr, PAT ₹332 Cr, EBITDA margin 22.4%, EPS ₹76.95. Year-on-year: revenue YoY -0...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for EPIGRAL
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track EPIGRAL alongside your other holdings
Unlock full EPIGRAL research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Epigral Ltd.?
NiveshIQ detects active intelligence signals for Epigral Ltd. (EPIGRAL) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Epigral Ltd.?
Epigral Ltd. is listed on NSE/BSE with a market capitalisation of ₹476,841.2L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.